Total Payments
$705,788
2024 Payments
$40,883
Companies
57
Transactions
1,848
Medicare Patients
423
Medicare Billing
$49,744
Payment Breakdown by Category
Other$422,668 (59.9%)
Consulting$202,090 (28.6%)
Travel$42,895 (6.1%)
Food & Beverage$35,309 (5.0%)
Research$1,786 (0.3%)
Education$1,040 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $418,668 | 187 | 59.3% |
| Consulting Fee | $202,090 | 60 | 28.6% |
| Travel and Lodging | $42,895 | 143 | 6.1% |
| Food and Beverage | $35,309 | 1,434 | 5.0% |
| Grant | $4,000 | 1 | 0.6% |
| Unspecified | $1,786 | 4 | 0.3% |
| Education | $1,040 | 19 | 0.1% |
Payments by Type
General
$704,002
1,844 transactions
Research
$1,786
4 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GENZYME CORPORATION | $270,065 | 304 | $0 (2024) |
| EMD Serono, Inc. | $114,500 | 179 | $0 (2024) |
| Biogen, Inc. | $106,581 | 262 | $0 (2024) |
| Mallinckrodt Hospital Products Inc. | $40,949 | 56 | $0 (2024) |
| Mallinckrodt Enterprises LLC | $34,702 | 37 | $0 (2019) |
| Celgene Corporation | $26,035 | 74 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $22,474 | 192 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $18,978 | 41 | $0 (2024) |
| Genentech USA, Inc. | $18,193 | 43 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $12,517 | 11 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $40,883 | 279 | Mallinckrodt Hospital Products Inc. ($21,727) |
| 2023 | $18,044 | 245 | E.R. Squibb & Sons, L.L.C. ($6,775) |
| 2022 | $51,454 | 292 | Mallinckrodt Hospital Products Inc. ($11,930) |
| 2021 | $57,758 | 248 | GENZYME CORPORATION ($19,449) |
| 2020 | $50,170 | 102 | Biogen, Inc. ($13,895) |
| 2019 | $157,011 | 174 | EMD Serono, Inc. ($50,731) |
| 2018 | $161,722 | 208 | GENZYME CORPORATION ($78,967) |
| 2017 | $168,745 | 300 | GENZYME CORPORATION ($94,653) |
All Payment Transactions
1,848 individual payment records from CMS Open Payments — Page 1 of 74
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $13.77 | General |
| Category: IMMUNOLOGY | ||||||
| 12/19/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | In-kind items and services | $18.00 | General |
| Category: Neurology | ||||||
| 12/18/2024 | Biogen, Inc. | VUMERITY (Drug) | Food and Beverage | In-kind items and services | $4.17 | General |
| Category: Neurology | ||||||
| 12/17/2024 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $24.46 | General |
| Category: NEUROLOGY | ||||||
| 12/12/2024 | BANNER LIFE SCIENCES, LLC | BAFIERTAM (Drug) | Food and Beverage | In-kind items and services | $10.86 | General |
| Category: Immune | ||||||
| 12/11/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $33.73 | General |
| 12/10/2024 | Genentech USA, Inc. | Ocrevus Zunovo (Biological) | Food and Beverage | In-kind items and services | $8.60 | General |
| Category: Immunology | ||||||
| 12/05/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $9.48 | General |
| Category: Neuroscience | ||||||
| 12/04/2024 | BANNER LIFE SCIENCES, LLC | BAFIERTAM (Drug) | Food and Beverage | In-kind items and services | $21.04 | General |
| Category: Immune | ||||||
| 12/04/2024 | Biogen, Inc. | VUMERITY (Drug) | Food and Beverage | In-kind items and services | $17.79 | General |
| Category: Neurology | ||||||
| 11/26/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $7.24 | General |
| Category: NEUROSCIENCE | ||||||
| 11/25/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $5.24 | General |
| Category: NEUROSCIENCE | ||||||
| 11/21/2024 | Vanda Pharmaceuticals Inc. | PONVORY (Drug) | Food and Beverage | In-kind items and services | $13.91 | General |
| Category: MULTIPLE SCLEROSIS | ||||||
| 11/21/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $7.77 | General |
| Category: Neuroscience | ||||||
| 11/20/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | In-kind items and services | $19.52 | General |
| Category: Immunology | ||||||
| 11/19/2024 | Amneal Pharmaceuticals LLC | CREXONT (Drug) | Food and Beverage | In-kind items and services | $20.97 | General |
| Category: NEUROLOGY | ||||||
| 11/14/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $19.98 | General |
| Category: IMMUNOLOGY | ||||||
| 11/14/2024 | Biogen, Inc. | VUMERITY (Drug) | Food and Beverage | In-kind items and services | $14.65 | General |
| Category: Neurology | ||||||
| 11/14/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $6.69 | General |
| Category: Neuroscience | ||||||
| 11/14/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $4.58 | General |
| Category: Neuroscience | ||||||
| 11/13/2024 | Genentech USA, Inc. | Ocrevus Zunovo (Biological) | Food and Beverage | In-kind items and services | $13.86 | General |
| Category: Immunology | ||||||
| 11/13/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $8.54 | General |
| Category: NEUROSCIENCE | ||||||
| 11/12/2024 | UCB, Inc. | Briviact (Drug) | Food and Beverage | In-kind items and services | $12.00 | General |
| Category: Neurology | ||||||
| 11/08/2024 | GENZYME CORPORATION | — | Consulting Fee | Cash or cash equivalent | $10,931.00 | General |
| 11/08/2024 | GENZYME CORPORATION | — | Travel and Lodging | In-kind items and services | $380.25 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| TERI-PRO: A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple S | GENZYME CORPORATION | $1,010 | 2 |
| Hair | GENZYME CORPORATION | $775.57 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 1 | 15 | 15 | $3,240 | $313.77 |
| 2022 | 3 | 139 | 188 | $50,175 | $19,789 |
| 2021 | 4 | 136 | 172 | $45,242 | $18,577 |
| 2020 | 6 | 133 | 142 | $40,551 | $11,064 |
Total Patients
423
Total Services
517
Medicare Billing
$49,744
Procedure Codes
14
All Medicare Procedures & Services
14 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 15 | 15 | $3,240 | $313.77 | 9.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 79 | 127 | $27,642 | $11,201 | 40.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 40 | 40 | $16,443 | $5,830 | 35.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 20 | 21 | $6,090 | $2,758 | 45.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 75 | 108 | $23,296 | $9,653 | 41.4% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 23 | 23 | $9,480 | $3,558 | 37.5% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 23 | 26 | $7,540 | $3,474 | 46.1% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 15 | 15 | $4,926 | $1,893 | 38.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 49 | 57 | $15,280 | $3,749 | 24.5% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 22 | 23 | $7,231 | $2,498 | 34.5% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 21 | 21 | $8,627 | $2,411 | 27.9% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 11 | 11 | $5,337 | $1,336 | 25.0% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 15 | 15 | $3,182 | $567.43 | 17.8% |
| 99441 | Physician telephone patient service, 5-10 minutes of medical discussion | Office | 2020 | 15 | 15 | $894.00 | $503.06 | 56.3% |
About Dr. Lori Travis, MD
Dr. Lori Travis, MD is a Neurology healthcare provider based in Phoenix, Arizona. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/11/2006. The National Provider Identifier (NPI) number assigned to this provider is 1093794885.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Lori Travis, MD has received a total of $705,788 in payments from pharmaceutical and medical device companies, with $40,883 received in 2024. These payments were reported across 1,848 transactions from 57 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($418,668).
As a Medicare-enrolled provider, Travis has provided services to 423 Medicare beneficiaries, totaling 517 services with total Medicare billing of $49,744. Data is available for 4 years (2020–2023), covering 14 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Phoenix, AZ
- Active Since 01/11/2006
- Last Updated 10/20/2022
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1093794885
Products in Payments
- AUBAGIO (Drug) $189,322
- ACTHAR (Biological) $75,651
- LEMTRADA (Drug) $48,143
- Rebif (Biological) $29,683
- TECFIDERA (Drug) $29,661
- ZEPOSIA (Drug) $21,491
- VUMERITY (Drug) $20,354
- Mavenclad (Drug) $18,553
- COPAXONE (Drug) $18,283
- Mavenclad (Biological) $17,278
- TYSABRI (Biological) $16,991
- Ozanimod (Drug) $15,678
- MAYZENT (Drug) $13,483
- OCREVUS (Biological) $12,688
- PLEGRIDY (Biological) $12,051
- AMPYRA (Drug) $11,979
- BAFIERTAM (Drug) $8,515
- NO PRODUCT DISCUSSED (Drug) $7,902
- KESIMPTA (Drug) $6,165
- Non-Covered Product (Drug) $5,109
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Phoenix
Barry Hendin, Md, MD
Neurology — Payments: $3.0M
Neurology $3.0M
Maria Ospina, Md, MD
Neurology — Payments: $1.7M
Neurology $1.7M
Dr. Suraj Muley, Md, MD
Neurology — Payments: $1.5M
Neurology $1.5M
Steve Chung, M.d, M.D
Neurology — Payments: $993,222
Neurology $993,222
Shafeeq Ladha, M.d, M.D
Neurology — Payments: $712,796
Neurology $712,796
Dr. Jeffrey Gitt, D.o, D.O
Neurology — Payments: $669,966
Neurology $669,966